Pharmaceutical

Avante Health Solutions Partners with Industry Leader Chronos Imaging LLC

Chronos Imaging develops the new MRC 200 0407 ROT-GS 1004 and MRC 200 0508 ROT GS 1003 replacement tubes, distributed…

1 month ago

CNS Pharmaceuticals Announces Acceptance of Three Abstracts for Poster Presentation at the Society of NueroOncology (SNO) 30th Annual Meeting

HOUSTON, TX / ACCESS Newswire / November 10, 2025 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical…

1 month ago

Aptevo Debuts First Trispecific Antibody Candidate, APVO451, with Preclinical Data Demonstrating Immune Activation in Hard-to-Treat Solid Tumors

First data on Aptevo's new molecule presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting SEATTLE, WASHINGTON /…

1 month ago

LEM Surgical Achieves Major US Clinical Milestone With Dynamis Robotic Surgical System

BERN, CH / ACCESS Newswire / November 10, 2025 / LEM Surgical, a leading innovator in hard tissue surgical robotics,…

1 month ago

Olympia Pharmaceuticals Launches OlympiaGO: A Convenient Hydration Drink Mix for Immune Support and Wellness

New product line offers three refreshing flavors designed to boost hydration, energy, and immunity, all while supporting a healthy lifestyle…

1 month ago

Codexis Announces Signing of Lease for GMP Manufacturing Facility

REDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for…

1 month ago

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

PONTE VEDRA, Fla., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics…

1 month ago

Anaptys Announces Phase 2 Trial of Rosnilimab Did Not Meet Primary or Secondary Endpoints at Week 12 in Moderate-to-Severe Ulcerative Colitis

Rosnilimab was safe and well tolerated with similar adverse event rates vs. placeboObserved expected pharmacology, including ~90% depletion of pathogenic…

1 month ago

Propanc Biopharma, Inc. Secures up to $100 Million Private Placement to Support Digital Asset Acquisition Strategy & Accelerate Company’s R&D Pipeline

Initial Investment of $1 Million Received from Hexstone Capital LLC Upon ClosingMELBOURNE, Australia, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Propanc…

1 month ago